restricted PEEP
ProcedurePatients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)
NCT Number: NCT03167580
The 'REstricted versus Liberal positive end-expiratory pressure in patients without Acute respiratory distress syndrome' (RELAx) trial is a national multicenter, open randomized controlled trial in ICU patients without ARDS at start of ventilation. It will be the first RCT comparing ventilation with the lowest possible positive end-expiratory pressure (PEEP) level with ventilation with the median PEEP level currently practiced in the Netherlands that recruits a sufficient number of patients to test the hypothesis that ventilation with the lowest possible PEEP level is non-inferior to ventilation with a PEEP level of 8 cm H2O with regard to objective and patient-relevant clinical endpoints.
Looking for future studies?
Notify Me18 year–100 year
All sexes
Interventional
Not applicable
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands
Research question:
Is mechanical ventilation with the lowest possible PEEP level, as compared to mechanical ventilation with the PEEP level currently practiced, non inferior in terms of the number of ventilator-free days at days 28 in patients without ARDS?
Study design:
National multicenter, non-inferiority, open randomized controlled trial in intubated and ventilated adult ICU patients without ARDS.
Centers:
13 centers in The Netherlands will participate in this trial:
Monitoring:
Monitoring of patients safety and reviewing of safety issues is performed by a designated independent Data Safety and Monitoring Board (DSMB).The DSMB watches over the ethics of conducting the study in accordance with the Declaration of Helsinki.
Study population:
Adult intensive care unit(ICU) patients without ARDS with an anticipated duration of ventilation of at least 24 hours, within 1 hour after initiation or admittance to the ICU if already intubated and ventilated admission.
Sample Size Calculation:
Group size calculation is focused on demonstrating non-inferiority. When the sample size in each is 445, an one-sided non-inferiority t-test (targeted at 0.05 significance level) for the difference in means of log-transformed normalized data has a 80% power to reject the null hypothesis that the number of VFD-28 in the 'restricted PEEP'-arm is inferior to the number of VFD-28 in the 'liberal PEEP'-arm by a margin of 10% anticipating on a coefficient of a variation of 0.70 (www.stichting-nice.nl), in favor or the alternative hypothesis that the number of VFD-28 in the 'restricted PEEP'-arm is non-inferior.
The choice for a margin of 10% is motivated by what is considered acceptable from a clinical point of view as the maximal acceptable reduction of the ventilator-free period for non-inferiority. Clinically this margin means that an increase of > 10% in the duration of mechanical ventilation will reduce the VFD-28 with > 12 hours (calculated over the expected mean duration of mechanical ventilation of 5 days) (www.stichting-nice.nl), which will be considered inferior. To allow for an anticipated drop out of 10% a total of 980 patients will be included.
Methods:
Patients in participating intensive care units (ICU) are screened for eligibility and randomized within one hour of initiation of invasive ventilation or, if already intubated and ventilated before admission, on ICU admission. Demographic data on screened patients regardless of meeting enrollment criteria will be recorded (registry: age, gender, type of surgery).
Randomization will be performed using a dedicated, password protected, SSL-encrypted website. Randomization sequence is generated by a dedicated computer randomization software program. Due to the nature of the intervention, blinding is not possible.
Patients are randomly assigned in a 1:1 ratio to the 'restricted PEEP'-arm (i.e. lowest possible PEEP level, 0-5 cm H2O) or to the 'liberal PEEP'-arm (i.e. a PEEP level of 8 cm H2O, the median PEEP level applied in the Netherlands)
The allowed ventilation modes are: volume-controlled or pressure-controlled ventilation, and pressure support ventilation. Automated modes, in particular those that automatically change PEEP and FiO2, are never allowed. With volume-controlled and pressure-controlled ventilation the inspiration-to-expiration ratio is set at 1:2. With volume-controlled ventilation the inspiration time and pause are set at 25% and 10%, respectively. With pressure support ventilation the highest possible pressure rise is chosen, and cycling off is set at 25%. Tidal volume size is between 6-8 ml/kg predicted body weight, which is calculated according to the following formula 50 + 0.91 x (centimeters of height - 152.4) for males and 45.5 + 0.91 x (centimeters of height - 152.4) for females. The respiratory rate is adjusted to obtain a normal arterial blood pH (7.35 to 7.45). In case of metabolic acidosis or alkalosis, a lower or higher than normal PaCO2 can be accepted, which is left to the discretion of the attending physician. Recruitment maneuvers are allowed when deemed necessary, but the decision to perform a recruitment maneuver is also left to the discretion of the attending physician.
These so-called down-titrations of the PEEP level are allowed as often as wanted, but with a minimum of three per ICU nurse shift.
Patients are weaned from the ventilator and tracheally extubated using the lowest PEEP level.
Patients are weaned of the ventilator and tracheally extubated using a PEEP level of 8 cm H2O. If preferred, the level of PEEP can be set at 5 cm H2O for one to two hours directly before tracheal extubation, left to the discretion of the attending physician.
For patients in whom the risk of severe hypoxemia could be become unacceptable during the trial (e.g., in patients who develop: ongoing cardiac ischemia due to cardiac infarction and failed revascularization, delayed cerebral ischemia after subarachnoid hemorrhage, increased and uncontrollable intracranial pressure (of ≥ 18 mmHg), necrotizing fasciitis or severe untreatable anemia such as with Jehovah's Witnesses), the target ranges for oxygenation can be increased to SpO2 and PaO2 of 94% to 96%, and 9 kPa to 11.5 kPa, respectively.
The attending physician decides when to tracheally extubate a patient, based on general extubation criteria (i.e. responsive and cooperative, adequate cough reflex, adequate oxygenation with FiO2 ≤ 0.4, hemodynamically stable, no uncontrolled arrhythmia and a rectal temperature > 36 Celsius and after successfully passing a spontaneous breathing trial (SBT) with a T-piece or ventilation with minimal support (pressure support level < 10 cm H2O) and FiO2 ≤ 0.4. In case SBTs are used, an SBT is judged as successful when the following criteria are met for at least 30 minutes, the attending physician takes the final decision for extubation:
Sedation follows the local guidelines for sedation in each participating unit. In general, these guidelines favor the use of analgo-sedation over hypno-sedation, use of bolus over continuous infusion of sedating agents, and the use of sedation scores.
Statistical Analysis:
Substudies:
Substudies of the RELAx study ('RELAxECHO', 'RELAxLUS' and 'RELAxBiomarkers') are performed in patients admitted to the ICU of the Academic Medical Center, Amsterdam and who are enrolled in the RELAx study. The protocol of each substudy is described in the appendices of the RELAx protocol: appendix IV 'RELAxECHO'; appendix V 'RELAxLUS' and appendix VI 'RELAxBiomarkers'. The link to the RELAx protocol including the appendices for substudies can be found under 'references'.
Enrolment of RELAx patient in the substudies started on 25th July 2018, 25th July 2018 and 4th December 2018 in the Academic Medical Center.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)
Patients are randomized and ventilated with liberal PEEP (the median PEEP level used in the Netherlands, 8 cm H2O)
Time frame: first 28 days after start of ventilation
The number of ventilation-free days, defined as the number of days from day 1 to day 28; the patient is alive and breathes without assistance of the mechanical ventilator, if the period of unassisted breathing lasted at least 24 consecutive hours.
Time frame: first 90 days after start of ventilation
Length of stay in the intensive care unit and in the hospital
Time frame: first 90 days after start of ventilation
Any death during ICU-, hospital-stay and within 90 days
Time frame: daily until detubation or day 28
development of ARDS according tot the Berlin definition, severe hypoxemia, severe atelectasis, severe atelectasis, pneumonia and pneumothorax.
Time frame: daily until detubation or day 28
Recruitment maneuver, prone positioning and bronchoscopy for opening atelectasis.
Time frame: daily until detubation or day 28
The number of ICU days with any use of vasopressors/inotropes for > 2 hours on a day.
Time frame: daily until detubation or day 28
Defined as the number of ICU days with any use of sedatives for > 2 hours on a day.
Time frame: daily until detubation or day 28
Incremental Cost Effectiveness Ratios (ICER) will be calculated by extra costs per TISS/NAS point, a valuable score reflecting workload and resource utilization in daily ICU practice.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
REstricted Versus Liberal Positive End-Expiratory Pressure in Patients Without Acute Respiratory Distress Syndrome
Acronym: RELAx
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04593810
Quality of Breathing, Ventilator-free Days
Genoa, Italy
View Trial DetailsNCT02153294
Ventilator-free Days
Amsterdam, Netherlands
View Trial DetailsNCT05188092
Deresuscitation, Edema
Arnhem, Gelderland, Netherlands
View Trial Details